Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

Next Previous
Trial Profile

A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AIM 102 (Primary)
  • Indications Allergic asthma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors AIM Therapeutics

Most Recent Events

  • 13 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
  • 22 Oct 2012 Status changed from recruiting to active, no longer recruiting, as reported in an AIM Therapeutics media release.
  • 22 Oct 2012 AIM Therapeutics anticipates that trial results will be available by the end of the first quarter, 2013.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top